These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27406983)

  • 1. A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.
    Toriyama S; Horinaka M; Yasuda S; Taniguchi T; Aono Y; Takamura T; Morioka Y; Miki T; Ukimura O; Sakai T
    Mol Cancer Ther; 2016 Sep; 15(9):2066-75. PubMed ID: 27406983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.
    Takamura T; Horinaka M; Yasuda S; Toriyama S; Aono Y; Sowa Y; Miki T; Ukimura O; Sakai T
    Oncol Rep; 2018 Feb; 39(2):627-632. PubMed ID: 29207153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
    Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
    Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
    Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
    Cao H; Cheng Y; You L; Qian J; Qian W
    Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.
    Jazirehi AR; Kurdistani SK; Economou JS
    J Immunol; 2014 Apr; 192(8):3981-9. PubMed ID: 24639349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis.
    Li Y; Jin X; Li J; Jin X; Yu J; Sun X; Chu Y; Xu C; Li X; Wang X; Kakehi Y; Wu X
    Urology; 2012 Apr; 79(4):968.e7-15. PubMed ID: 22244504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
    Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
    Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.
    Moon DO; Kim MO; Choi YH; Kim GY
    Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.